Beijing Meikang Geno-Immune Biotechnology

Beijing Meikang Geno-Immune Biotechnology is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of advanced cell and gene therapies for cancer. The company leverages its proprietary 4th-generation safety-engineered CAR (4SCAR) platform, which integrates a suicide gene system to improve the safety and controllability of T-cell therapies. Their robust pipeline includes multiple CAR-T candidates targeting hematological malignancies such as B-cell lymphoma, leukemia, and multiple myeloma. Beijing Meikang operates in close collaboration with the Shenzhen Geno-Immune Medical Institute to translate cutting-edge immunotherapy research into clinical applications. The company is currently advancing several programs through Phase 1 and Phase 2 clinical trials across various hospital sites in China.